Purpose Recent guidelines suggest that a single prolactin measurement is adequate to confirm hyperprolactinaemia. This may lead to unnecessary investigation of artefactual hyperprolactinaemia. Prolactin measurement drawn from an indwelling cannula after rest removes stress as a confounding variable. The objective was to determine the frequency of true hyperprolactinaemia amongst patients referred following a single prolactin measurement. Methods A cannulated study was considered if prolactin on referral ('Referral Prolactin') was\5,500 mU/L (260 ng/mL) but [410 mU/L (19 ng/mL) in males or [510 mU/L (24 ng/mL) in females, irrespective of clinical context. Case-notes of 267 patients undergoing cannulated prolactin measurement over a 10-year period (2000-2010) were reviewed. Pre-existing pituitary disease, dopamine antagonist use, and macroprolactinaemia were excluded. Morning ante-cubital vein cannulation was followed immediately by withdrawal of 'Repeat Prolactin' sample. After 120-min bed-rest, 'Resting Prolactin' was withdrawn through the cannula. Results 235 patients were included for analysis. 64 (27 %) were within normal range; following Repeat Prolactin in 41 (17 %) and Resting Prolactin in 23 (9 %) cases. Referral Prolactin was higher in patients with true hyperprolactinaemia, 1,637 ± 100 mU/L (77.2 ± 4.7 ng/mL) than with artefactual hyperprolactinaemia, 1,122 ± 68 mU/L (52.9 ± 3.2 ng/mL; P \ 0.001) but there was substantial overlap. 21 out of 171 cases (12 %) with true hyperprolactinaemia had a macroadenoma. Presenting symptoms did not predict true hyperprolactinaemia. Referral Prolactin of 2,000 mU/L (94 ng/mL) had 97 % specificity to identify true hyperprolactinaemia. Conclusions Reliance on a single, non-rested prolactin value may lead to over-diagnosis of hyperprolactinaemia. A resting sample should be considered with random values \2,000 mU/L (94 ng/mL).
Introduction
Hyperprolactinaemia is one of the most common endocrine disorders of the hypothalamic-pituitary axis [1] . It is more commonly diagnosed in women than in men due to the symptoms of menstrual disturbance or galactorrhoea and due to testing for subfertility. The prevalence of hyperprolactinaemia varies from 0.2 % in an unselected normal adult population to 17 % in women with reproductive disorders [2, 3] . The prevalence is higher still in those with symptoms attributable to hyperprolactinaemia: up to 25 % among women with galactorrhoea and 70 % among women with amenorrhea and galactorrhoea [4] . Hyperprolactinaemia can result from physiological stimuli such as sleep or exercise or from pathological causes including medication use (primarily dopamine antagonist drugs), pituitary prolactinoma, compression of the pituitary stalk, disease of the hypothalamus, primary hypothyroidism, chest wall lesions and renal failure. Laboratory confirmation of hyperprolactinaemia is essential for accurate diagnosis. A major challenge has been the correct differentiation of patients with true hyperprolactinaemia, who have supra-physiological concentrations of bioactive monomeric prolactin, from those with macroprolactinaemia, who have increased concentrations of macroprolactin together with normal concentrations of monomeric prolactin. This difficulty has been overcome by the routine use of polyethylene glycol precipitation [5] . However, the laboratory is unable to comment on the conditions during which the sample was taken that can impact on the measured value. Guidelines for the diagnosis and treatment of hyperprolactinaemia have recently been published by The Endocrine Society that advise that a single measurement of prolactin in a blood sample obtained at any time of the day will usually be adequate to document hyperprolactinaemia, as long as the sample was withdrawn without excessive venepuncture stress [6] . However, a stressful venepuncture is subjective and may be difficult to determine. For over 10 years we have used a cannulated prolactin measurement in patients with hyperprolactinaemia to distinguish true cases from artefactual hyperprolactinaemia.
Following publication of the Endocrine Society guidelines, we conducted a review of our series of cannulated prolactin studies to determine whether this test has a role in the investigation of patients found to have an elevated prolactin on a single measurement.
Patients and methods
Case notes of consecutive patients who underwent a cannulated resting prolactin measurement at a referral centre over a 10-year period (2000-2010) were reviewed. From these records, information on symptoms, imaging investigations and diagnoses were obtained. All male and female patients over 16 years of age were included with an initial prolactin above the laboratory reference range of 510 mU/L (24 ng/mL) in females or 410 mU/L (19 ng/mL) in males and\109 upper reference range (5,500 mU/L or 260 ng/mL). Patients were referred with galactorrhoea, irregular menses, infertility, headache, visual field anomaly, an incidental finding of hyperprolactinaemia, features of hyperandrogenaemia (females) or erectile dysfunction (males). Patients were excluded if liver, renal or thyroid disease were present; were taking medications known to induce hyperprolactinaemia; or were pregnant. No patients had previous pituitary disease. All samples with prolactin greater than the reference range were routinely re-measured after polyethylene glycol precipitation. Only the 23-kDa monomeric prolactin concentration was used for this analysis. Samples of 150-kDa macroprolactin causing hyperprolactinaemia (macroprolactinaemia [40 %) were excluded from analysis. We recorded data from the initial presentation only.
The primary outcome was the proportion of patients referred with hyperprolactinaemia found to have normoprolactinaemia after a cannulated study. We also examined which symptom(s) at presentation were predictive of true hyperprolactinaemia.
The initial measurement of prolactin from primary or secondary care that led to a review by our endocrine service was termed the 'Referral Prolactin'. As a study of prolactin management in secondary care (rather than tertiary care), the patients were generally referred from local primary care centres or by other departments within our hospital. Approximately 90 % of the Referral values were measured at the same laboratory as the Repeat/Resting values. Interassay variability was therefore thought unlikely to explain any change in prolactin. The same assay was used for Repeat and Resting samples. All tests were conducted between 09:00 and 12:00 in a quiet room at the endocrine investigation day unit. An intravenous cannula was placed in the antecubital fossa and the baseline sample withdrawn ('Repeat Prolactin'). Patients remained recumbent for 120 min until the second sample was withdrawn from the indwelling cannula ('Resting Prolactin'). Prolactin was measured by sandwich immunoassay using an ADVIA Centaur platform (Siemens Healthcare, Frimley, UK). The reference range at our laboratory for prolactin is 100-510 mU/L (4.7-24 ng/L) for women and 100-410 mU/L (4.7-19 ng/mL) for males. The standardization of the ADVIA Centaur prolactin assay used in this study is traceable to the World Health Organisation (WHO) 3rd International standard for human prolactin (84/500) [7] . At our centre, the intra-and inter-assay coefficient of variation (cv) of serum prolactin at 561 mU/L (26 ng/mL) is 2.5 and 5.3 %, and at 2,500 mU/L (118 ng/ mL) is 4.4 and 4.9 %. Subjects required at least one of the following indications for a Resting Prolactin measurement: borderline raised Referral Prolactin (510-600 mU/L; 24-28.3 ng/mL); no clinical features of hyperprolactinaemia; clinical suspicion of stress-induced hyperprolactinaemia. Statistical analyses were performed using SPSS for Windows (version 17.0; SPSS, Chicago, USA). Results are reported as mean ± SEM (normally distributed datasets). The Kolmogorov-Smirnov test was employed as a test of normality. Kruskal-Wallis one-way analysis of variance was used to compare the Referral Prolactin with true hyperprolactinaemia and normalisation of prolactin with repetition or rest. Mann-Whitney U test was used to compare Referral Prolactin between true hyperprolactinaemia and normoprolactinaemia. Comparison of symptom prevalence between normoprolactinaemic and hyperprolactinaemic patient groups was made by the Fisher's test for categorical variables. The unpaired t test was used for measuring continuous variables between true hyperprolactinaemia and normoprolactinaemia groups. An ROC curve was constructed to define the ability of the Referral Prolactin to identify true hyperprolactinaemia from the referral sample. A P \ 0.05 was considered statistically significant. A prolactin concentration of 21.2 mU/L is equivalent to 1 ng/mL.
Results
Over the study period, 267 patients underwent a cannulated prolactin test. Ten patients with pre-existing pituitary disease were excluded, 16 patients were excluded due to concomitant dopamine antagonist therapy. Six patients had significant macroprolactin in the sample (range of macroprolactin 50-88 %) and were therefore not included. A total of 235 patients' data were included for analysis.
The Referral Prolactin was higher in those with true hyperprolactinaemia (Table 1 ; Fig. 1 ) than those whose prolactin normalised with rest or repetition, although there was substantial overlap. In 41 cases (17 %), the Repeat Prolactin was normal (Fig. 2a) . The maximal Referral Prolactin that was within the normal range on repetition was (3,024 mU/L or 126 ng/mL; Figs. 1, 2a) .
In 23 patients (9 %) the Resting Prolactin was normal at 120 min following an elevated prolactin on the repeat sample (zero minutes following cannulation) (Fig. 2b) . In these cases, the range in reduction of prolactin was 8-80 % and the absolute reduction in serum prolactin was 44-749 mU/L (2.1-35.3 ng/mL). The highest Repeat Prolactin concentration at zero minutes that normalised at 120 min was 1,123 mU/L (53 ng/mL), (Fig. 2b) . In patients with true hyperprolactinaemia, the mean change in prolactin on resting was a reduction of 14.2 ± 2.0 %. In this group, three patients exhibited a drop of 50 % or more but remained within the hyperprolactinaemic range. True hyperprolactinaemia was found in 17 of 28 (61 %) patients Overall, 64 (27 %) cases referred to the endocrine unit with hyperprolactinaemia and tested with a cannulated prolactin study were found to have a normal serum prolactin.
Of those patients with confirmed hyperprolactinaemia, 85 % underwent an MRI scan. In 95 (65 %) of these patients MRI demonstrated a significant pituitary abnormality. The reasons for MRI not being performed in cases of confirmed hyperprolactinaemia were: pregnancy before imaging could be undertaken; failure to attend imaging; lost to follow-up. Our protocol did not include a routine MRI in those shown to have a normal prolactin with repeat or resting samples. However, in six patients (9 %) an MRI was requested prior to endocrine evaluation. One patient in the normoprolactinaemic group was found to have a 10 mm pituitary lesion (Table 1 ) and underwent hypophysectomy: no immunohistochemical staining was evident, consistent with a non-functioning adenoma.
An ROC curve was constructed to establish possible cut-off values for 'accepting' a single Referral Prolactin. We tested to define the level of Referral Prolactin that had a high specificity for predicting true hyperprolactinaemia: that is, minimising the number of false positive results following a cannulation study. The area under the ROC curve for the referral prolactin to predict true hyperprolactinaemia in women was 0.71 (95 % CI 0.63-0.79) (Fig. 3) . Referral Prolactin of 2,040 mU/L or 96.2 ng/mL (94 upper range of normal) had 97 % specificity to detect true hyperprolactinaemia in women (Table 2) .
Symptoms on referral

Females
To test whether the presence and/or type of symptom on referral predicted true hyperprolactinaemia, cases were grouped according to their final categorisation: normo-and hyperprolactinaemia. Although cases of infertility were included in the sample, these were all in the context of menstrual irregularity and therefore not counted separately. In both groups menstrual irregularity was the most frequent symptom at presentation. Galactorrhoea was the only symptom that was significantly more common amongst patients with true hyperprolactinaemia (Fig. 4) . Overall, clinical symptoms were not a reliable guide.
Males
18 males were studied. Males were older (48.1 ± 3.3 years) than the females (36.8 ± 0.7 years; P = 0.03). Referral prolactin was 1,199 ± 355 mU/L (56.6 ± 16.7 ng/mL) compared to 1,701 ± 126 mU/L (80.2 ± 5.9 ng/mL) in women; P = NS. Males presented with either erectile dysfunction and/or loss of libido (n = 16), or with hyperprolactinaemia diagnosed incidentally where the indication for testing was not clear (n = 2). Testosterone data were available in 16 patients. The serum testosterone was lower in patients with true hyperprolactinaemia (8.0 ± 2.8 vs. 13.7 ± 4.8 nmol/L; P = 0.03). The range of plasma testosterone in those whose prolactin did not normalise was 2.3-13.5 nmol/L.
Discussion
We conducted a large consecutive study at a single centre to determine the frequency of true hyperprolactinaemia amongst a cohort of patients referred for evaluation of a single prolactin measurement. This study has shown that 28 % of patients referred with hyperprolactinaemia had normal serum prolactin during a cannulated study. Our data has also shown that a Referral Prolactin of just over 2,000 mU/L (94 ng/mL) has 97 % specificity to determine true hyperprolactinaemia. We suggest that this is a suitable threshold value above which confirmatory tests are not required. The presence or type of symptoms at the time of presentation was a poor guide as to whether true hyperprolactinaemia was present. Recent Endocrine Society guidelines state that a single measurement of prolactin in a blood sample obtained at any time of the day is usually adequate to document hyperprolactinaemia, as long as it was obtained without excessive venepuncture stress [6] . However, the data from this study shows that the false positive rate from such an approach would be high. Stress is subjective and may be difficult to determine. Our data have shown that a referral prolactin of up to 3,024 mU/L (143 ng/mL) can be normal on repeat testing. It has previously been considered that physical and psychological stress would rarely cause prolactin to exceed 850 mU/L (40 ng/mL) [8] , but this study suggests that the effect of stress may be greater than previously thought, as evidenced by a prolactin over 2,000 mU/L (94 ng/mL) normalising after 120-min of rest. Our data is consistent with a study published in the era before routine testing for macroprolactin, of the effect of rest on serum prolactin [9] . In that study, 20 out of 70 patients (28 %) who had shown initially high serum prolactin levels in two random blood samples were found to be euprolactinaemic. Nine of these patients normalised upon repetition and a further 11 after 60-min rest. A more recent study, involving measurement of prolactin after just 15-min of rest, reported that no patients with serum prolactin [20 ng/mL (420 mU/L) normalised by 15-min [10] . This is likely to have been due to an insufficient duration of rest as it has been shown that following a needle-stick injury, plasma prolactin concentration progressively declines for up to 105-min after injury [11] . This is consistent with the reported 20-min half-life of prolactin [12] .
The causes for normalisation of prolactin with repetition are likely to be related to the pattern of its secretion and the effect of stress. Prolactin is released in a pulsatile manner with up to 14 peaks per 24-h. The mean pulse amplitude may show a 50 % increase above the preceding nadir [13] . Prolactin concentrations also show a circadian variation. The maximum concentration is reached about 4 h after the onset of sleep and may be over 150 % of the 24-h mean, the minimum concentration is reached about 6 h after waking and is 40 % of the 24-h mean [14, 15] . As a result, prolactin concentrations can vary up to four-fold depending on the time of day or night. Furthermore, in females, prolactin concentrations are higher during the middle and second half of the menstrual cycle. The difficulty of defining a normal range for prolactin is compounded by the effect of body mass and nutritional status. Obesity is associated with hyperprolactinaemia [15] . Hyperprolactinaemia is usually considered a consequence of obesity, although changed dopaminergic tone has been suggested to promote obesity [16, 17] . Prolactin measurement should be made in a fasting state as feeding can acutely trigger prolactin release [18] . The reference range at our laboratory is provided by the manufacturer of the prolactin assay. Although this range should account for physiological variation, it is based on relatively few controls and, although subjects are rested, is not based upon cannulated data. Some laboratories also report separate intervals for premenopausal and post-menopausal women. In one study, the upper reference limit for men was reported as 17 ng/mL (360 mU/L) compared with 46 ng/mL (975 mU/L) for premenopausal women [19] , and 25 ng/mL (530 mU/L) for post-menopausal women [20] . Alternative assays may yield prolactin levels that are lower or higher. The periodicity of prolactin secretion is not sufficient to account for the normalisation of prolactin (from Repeat to Resting) that occurred in 23 patients. The mean reduction in prolactin from Repeat to Resting in our study was 374.2 mU/L, 95 % CI 278.3-470.2 mU/L (17.7 ng/mL; 95 % CI 13.1-22.2 ng/mL). This is far in excess of the cosinor amplitude of prolactin secretion, which is 23.7 ± 2.1 mU/L (1.1 ± 0.1 ng/mL) in men and 40.7 ± 3.6 mU/L (1.9 ± 0.2 ng/mL) in women [15] . Furthermore, it has been shown that the mesor prolactin between 9 a.m. and midday (the hours at which we performed the cannulated studies) shows minimal change [15] . Reduction in prolactin with rest is therefore likely due to resolution of a stress response. The challenge is to predict in which patients this stress response is occurring. It is debatable whether a difficult venepuncture could, by itself, raise prolactin within the first few minutes after cannulation. To our knowledge, no such studies have been done. In two patients, the Repeat Prolactin was higher than the Referral Prolactin, this may be due to the cannulation procedure being more painful than a routine venepuncture at phlebotomy. No studies have been done comparing the prolactin concentration following these methods of sampling, by the same practitioner. It is possible that anticipatory stress, rather than venepuncture technique, is sufficient to lead to an elevated prolactin concentration at the time of repeat sampling [21] . Resting prolactin identified 23 cases of normoprolactinaemia, after the Repeat Prolactin remained elevated. This suggests a role for the cannulated prolactin study but it may not be feasible to incorporate into routine clinical practice due to resource implications. Repeat Prolactin identified 41 cases of normoproalctinaemia, a second venepuncture might therefore be more practical for cases with a degree of clinical uncertainty, prior to consideration of a cannulated study if this remains elevated. There was a large overlap in the Referral prolactin between cases that did, or did not, normalise with rest. We therefore looked at whether symptoms at referral were predictive of true hyperprolactinaemia. Galactorrhoea was more prevalent in the hyperprolactinaemia group than those with normal prolactin after formal investigation. Galactorrhoea has been reported to occur in only one-third of patients with hyperprolactinaemia (possibly due to inadequate oestrogenic or progestational priming of the breast), but was closer to 50 % in our series [22] . Perhaps surprisingly, menstrual disturbance did not predict the presence of true hyperprolactinaemia. Premenopausal women with hyperprolactinaemia usually present with oligo-or amenorrhoea, and occasionally menorrhagia. However, it is recognised that menstrual irregularities may not be seen with mild hyperprolactinaemia [23, 24] . It may be that the reference range provided by the manufacturer lacks specificity for pre-menopausal women and local reference ranges may be developed to overcome this issue. Hyperprolactinaemia will suppress hypothalamic GnRH secretion leading to low testosterone in males (often presenting with erectile dysfunction). In our study 'true' hyperprolactinaemic males had lower plasma testosterone than normoprolactinaemic males and therefore it may be particularly important to exclude spurious high prolactin in males with normal testosterone. A strength of this study was that all notes were reviewed to ensure that no patients were using dopamine antagonist therapy. Additionally, no patients were commenced on dopamine agonist therapy between Referral Prolactin and repeat testing. Another advantage was that macroprolactin was excluded from all samples. We do not routinely repeat cannulated studies as part of our clinical practice and therefore do not have data on the reproducibility of the cannulation procedure.
Unless artefactual hyperprolactinaemia is excluded, further investigation with magnetic resonance imaging might be undertaken. Some studies have suggested that up to 10 % of the general population demonstrate an abnormality consistent with an incidental pituitary adenoma on imaging, which could lead to a misdiagnosis of microprolactinoma unless artefactual hyperprolactinaemia is identified [25] . It is well recognised that even in normoprolactinaemic patients there may be an improvement in galactorrhoea (and even prolactin) upon treatment with dopamine agonists. Coupled with a falsely raised prolactin concentration, this could lead to an over-diagnosis of microprolactinoma.
This study suggests that there is a role for repeat biochemical testing to diagnose normoprolactinaemic cases, which may mean that further imaging studies and the use of dopamine agonist measurement are not necessary. We suggest that this is particularly true in males with no other biochemical evidence of reproductive axis involvement.
Conclusion
Reliance on a single, non-rested prolactin value may lead to an over-diagnosis of hyperprolactinaemia and prolactin microadenoma. Potentially, this could result in further, unnecessary investigation and potentially unnecessary treatment. A single prolactin value between 500 and 2,000 mU/L (24-94 ng/mL) should be confirmed with a cannulated study.
